$ARDX

RAAB MICHAEL sold $211K of ARDX

RAAB MICHAEL (President & CEO) sold 41,668 shares of ARDELYX, INC. (ARDX) at $5.06 ($0.21M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RAAB MICHAEL
Published Jul 17, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

Because the sale is under a pre-arranged 10b5-1 plan, it is typically treated as lower-signal than discretionary selling, reducing expected fundamental impact.

02

Market read

Traders may note the insider sale for sentiment, but there is no new company-specific catalyst beyond the transaction details.

03

What to watch

The filing does not indicate whether other insiders sold/bought around the same time, nor does it provide context on tax or diversification needs.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-17 after-hours, reflecting a 2026-07-15 sale

Background

The article is an SEC Form 4 insider transaction disclosure for ARDELYX, INC. (ARDX).

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

SEC Form 4 shows ARDX CEO Raab Michael sold 41,668 shares on 2026-07-15 under a 10b5-1 plan for about $210,923.

Expected impact

Likely minimal immediate price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, regulatory, or financial datapoint.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None.

None.

Counterpoint

Insider sales under 10b5-1 can be purely liquidity-driven and may not reflect bearish expectations.

Key entities

  • ARDX

    Ardelyx, Inc., the company whose CEO insider sale is disclosed.

  • RAAB MICHAEL

    President & CEO of Ardelyx, reported open-market sale of shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMedAI 8/10

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.

$ARDXHighAI 9/10

Why is Ardelyx stock plunging today?

Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.

$ARDXMed

ARDELYX, INC. (ARDX): Results of Operations and Financial Condition

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow